linvoseltamab + daratumumab

**Linvoseltamab + daratumumab** is a combination investigational therapy being studied for the treatment of **multiple myeloma**. Linvoseltamab is a bispecific monoclonal antibody that acts as a T-cell engager, binding both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T-cells to promote targeted cell killing. Daratumumab is a monoclonal antibody targeting CD38, a glycoprotein highly expressed on multiple myeloma cells, and mediates tumor cell death via a variety of immune-dependent mechanisms. This combination aims to leverage complementary mechanisms by simultaneously engaging T-cells for tumor cytotoxicity (linvoseltamab) and inducing immune-mediated destruction and immunomodulation (daratumumab). Linvoseltamab is developed by Regeneron; daratumumab was developed by Janssen and Genmab and is marketed as Darzalex. The phase 1/2 clinical trial NCT05137054 is evaluating this combination, particularly in relapsed/refractory multiple myeloma[1][3][5][6].